223 related articles for article (PubMed ID: 38464258)
1. PIKfyve controls dendritic cell function and tumor immunity.
Choi JE; Qiao Y; Kryczek I; Yu J; Gurkan J; Bao Y; Gondal M; Tien JC; Maj T; Yazdani S; Parolia A; Xia H; Zhou J; Wei S; Grove S; Vatan L; Lin H; Li G; Zheng Y; Zhang Y; Cao X; Su F; Wang R; He T; Cieslik M; Green MD; Zou W; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38464258
[TBL] [Abstract][Full Text] [Related]
2. Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy.
Bao Y; Qiao Y; Choi JE; Zhang Y; Mannan R; Cheng C; He T; Zheng Y; Yu J; Gondal M; Cruz G; Grove S; Cao X; Su F; Wang R; Chang Y; Kryczek I; Cieslik M; Green MD; Zou W; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2023 Dec; 120(49):e2314416120. PubMed ID: 38011559
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.
Kumar A; Ramani V; Bharti V; de Lima Bellan D; Saleh N; Uzhachenko R; Shen C; Arteaga C; Richmond A; Reddy SM; Vilgelm A
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230537
[TBL] [Abstract][Full Text] [Related]
4. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade.
Luo Y; Shreeder B; Jenkins JW; Shi H; Lamichhane P; Zhou K; Bahr DA; Kurian S; Jones KA; Daum JI; Dutta N; Necela BM; Cannon MJ; Block MS; Knutson KL
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37918918
[TBL] [Abstract][Full Text] [Related]
5. Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer.
Qiao Y; Choi JE; Tien JC; Simko SA; Rajendiran T; Vo JN; Delekta AD; Wang L; Xiao L; Hodge NB; Desai P; Mendoza S; Juckette K; Xu A; Soni T; Su F; Wang R; Cao X; Yu J; Kryczek I; Wang XM; Wang X; Siddiqui J; Wang Z; Bernard A; Fernandez-Salas E; Navone NM; Ellison SJ; Ding K; Eskelinen EL; Heath EI; Klionsky DJ; Zou W; Chinnaiyan AM
Nat Cancer; 2021 Sep; 2():978-993. PubMed ID: 34738088
[TBL] [Abstract][Full Text] [Related]
6. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
7. Small molecule AZD4635 inhibitor of A
Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
[TBL] [Abstract][Full Text] [Related]
8. Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation.
Sbrissa D; Naisan G; Ikonomov OC; Shisheva A
PLoS One; 2018; 13(9):e0204532. PubMed ID: 30240452
[TBL] [Abstract][Full Text] [Related]
9. CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses.
He M; Roussak K; Ma F; Borcherding N; Garin V; White M; Schutt C; Jensen TI; Zhao Y; Iberg CA; Shah K; Bhatia H; Korenfeld D; Dinkel S; Gray J; Ulezko Antonova A; Ferris S; Donermeyer D; Lindestam Arlehamn C; Gubin MM; Luo J; Gorvel L; Pellegrini M; Sette A; Tung T; Bak R; Modlin RL; Fields RC; Schreiber RD; Allen PM; Klechevsky E
Science; 2023 Feb; 379(6633):eabg2752. PubMed ID: 36795805
[TBL] [Abstract][Full Text] [Related]
10. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
[TBL] [Abstract][Full Text] [Related]
11. Human CD34
van Eck van der Sluijs J; van Ens D; Brummelman J; Heister D; Sareen A; Truijen L; van Ingen Schenau DS; Heemskerk MHM; Griffioen M; Kester MGD; Schaap NPM; Jansen JH; van der Waart AB; Dolstra H; Hobo W
Cell Mol Life Sci; 2023 Sep; 80(10):298. PubMed ID: 37728691
[TBL] [Abstract][Full Text] [Related]
12. PIKfyve inhibitor cytotoxicity requires AKT suppression and excessive cytoplasmic vacuolation.
Ikonomov OC; Altankov G; Sbrissa D; Shisheva A
Toxicol Appl Pharmacol; 2018 Oct; 356():151-158. PubMed ID: 30098992
[TBL] [Abstract][Full Text] [Related]
13. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
14. A nonredundant role for canonical NF-κB in human myeloid dendritic cell development and function.
van de Laar L; van den Bosch A; van der Kooij SW; Janssen HL; Coffer PJ; van Kooten C; Woltman AM
J Immunol; 2010 Dec; 185(12):7252-61. PubMed ID: 21076069
[TBL] [Abstract][Full Text] [Related]
15. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
[TBL] [Abstract][Full Text] [Related]
16. The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors.
Scheuerpflug A; Ahmetlić F; Bauer V; Riedel T; Röcken M; Mocikat R
Cancer Immunol Immunother; 2021 May; 70(5):1343-1350. PubMed ID: 33141285
[TBL] [Abstract][Full Text] [Related]
17. B-cell non-Hodgkin lymphoma: Selective vulnerability to PIKFYVE inhibition.
Gayle S; Landrette S; Beeharry N; Conrad C; Hernandez M; Beckett P; Ferguson SM; Xu T; Rothberg J; Lichenstein H
Autophagy; 2017 Jun; 13(6):1082-1083. PubMed ID: 28350209
[TBL] [Abstract][Full Text] [Related]
18. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
19. Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations.
Ikonomov OC; Sbrissa D; Shisheva A
Toxicol Appl Pharmacol; 2019 Nov; 383():114771. PubMed ID: 31628917
[TBL] [Abstract][Full Text] [Related]
20. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.
Gayle S; Landrette S; Beeharry N; Conrad C; Hernandez M; Beckett P; Ferguson SM; Mandelkern T; Zheng M; Xu T; Rothberg J; Lichenstein H
Blood; 2017 Mar; 129(13):1768-1778. PubMed ID: 28104689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
